StockData

Cartesian Therapeutics, Inc. (RNAC) stock

RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.12+0.04 (+0.66%)

Close on Nov 17, 2026Market cap $185.16MP/E –Yield –

Cartesian Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Cartesian Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$155.36M. For fiscal 2025 it was -$143.41M. The highest annual figure on record is $14.54M in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$143.41M–
FY2024Dec 31, 2024-$43.90M–
FY2023Dec 31, 2023-$86.42M-694.4%
FY2022Dec 31, 2022$14.54M–
FY2021Dec 31, 2021-$4.60M–
FY2020Dec 31, 2020-$56.82M–
FY2019Dec 31, 2019-$52.46M–
FY2018Dec 31, 2018-$65.02M–
FY2017Dec 31, 2017-$63.78M–
FY2016Dec 31, 2016-$34.67M–
FY2015Dec 31, 2015-$25.30M–
FY2014Dec 31, 2014-$15.40M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$29.16M–
Q1 FY2026Mar 31, 2026-$26.50M–
Q4 FY2025Dec 31, 2025-$78.64M–
Q3 FY2025Sep 30, 2025-$21.07M–
Q2 FY2025Jun 30, 2025-$21.81M-258.5%
Q1 FY2025Mar 31, 2025-$21.89M–
Q4 FY2024Dec 31, 2024-$26.73M–
Q3 FY2024Sep 30, 2024-$17.58M–
Q2 FY2024Jun 30, 2024$13.76M–
Q1 FY2024Mar 31, 2024-$13.35M–
Q4 FY2023Dec 31, 2023-$36.33M–
Q3 FY2023Sep 30, 2023-$13.07M–
Q2 FY2023Jun 30, 2023-$18.64M-234.5%
Q1 FY2023Mar 31, 2023-$18.38M-270.6%
Q4 FY2022Dec 31, 2022-$8.50M-308.3%
Q3 FY2022Sep 30, 2022-$1.60M–
Q2 FY2022Jun 30, 2022$13.86M+2966.4%
Q1 FY2022Mar 31, 2022$10.77M–
Q4 FY2021Dec 31, 2021$4.08M–
Q3 FY2021Sep 30, 2021-$1.97M–
Q2 FY2021Jun 30, 2021$452.00K–
Q1 FY2021Mar 31, 2021-$7.16M–
Q4 FY2020Dec 31, 2020-$7.90M–
Q3 FY2020Sep 30, 2020-$13.73M–
Q2 FY2020Jun 30, 2020-$16.37M–
Q1 FY2020Mar 31, 2020-$18.82M–
Q4 FY2019Dec 31, 2019-$12.57M–
Q3 FY2019Sep 30, 2019-$11.79M–
Q2 FY2019Jun 30, 2019-$16.24M–
Q1 FY2019Mar 31, 2019-$11.86M–
Q4 FY2018Dec 31, 2018-$14.50M–
Q3 FY2018Sep 30, 2018-$15.94M–
Q2 FY2018Jun 30, 2018-$18.77M–
Q1 FY2018Mar 31, 2018-$15.81M–
Q4 FY2017Dec 31, 2017-$19.28M–
Q3 FY2017Sep 30, 2017-$13.85M–
Q2 FY2017Jun 30, 2017-$15.87M–
Q1 FY2017Mar 31, 2017-$14.78M–
Q4 FY2016Dec 31, 2016-$13.86M–
Q3 FY2016Sep 30, 2016-$7.47M–

More Cartesian Therapeutics figures

See a number that looks wrong?